Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
value - The stock trades at 3.5x price/sales and 9.2x EV/EBITDA, below many specialty pharma peers…
Rising interest rates create modest headwinds through two channels: (1) higher discount rates compress valuation multiples…
Watch on earnings: Dysport quarterly sales growth by region and therapeutic vs aesthetic mix, particularly US neurology channel penetration, Somatuline prescription volume trends (TRx data) and net pricing realization in US market, Pipeline milestone achievements: palovarotene regulatory interactions, early-stage rare disease asset progression.
One Sentence Summary:
Ipsen: the story is balanced — dysport volume growth and market share gains versus allergan's botox in therapeutic spasticity indications.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
